NO944929L - Fremgangsmåte for å inhibere CNS-problemer i post-menopausale kvinner - Google Patents
Fremgangsmåte for å inhibere CNS-problemer i post-menopausale kvinnerInfo
- Publication number
- NO944929L NO944929L NO944929A NO944929A NO944929L NO 944929 L NO944929 L NO 944929L NO 944929 A NO944929 A NO 944929A NO 944929 A NO944929 A NO 944929A NO 944929 L NO944929 L NO 944929L
- Authority
- NO
- Norway
- Prior art keywords
- post
- procedure
- menopausal women
- inhibiting
- chem
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/171,388 US6417198B1 (en) | 1993-12-21 | 1993-12-21 | Methods of inhibiting CNS problems in post-menopausal women |
Publications (2)
Publication Number | Publication Date |
---|---|
NO944929D0 NO944929D0 (no) | 1994-12-19 |
NO944929L true NO944929L (no) | 1995-06-22 |
Family
ID=22623561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO944929A NO944929L (no) | 1993-12-21 | 1994-12-19 | Fremgangsmåte for å inhibere CNS-problemer i post-menopausale kvinner |
Country Status (22)
Country | Link |
---|---|
US (2) | US6417198B1 (ja) |
EP (1) | EP0659413B1 (ja) |
JP (1) | JPH07196502A (ja) |
KR (1) | KR950016742A (ja) |
CN (1) | CN1107332A (ja) |
AT (1) | ATE206920T1 (ja) |
AU (1) | AU692491B2 (ja) |
CA (1) | CA2138459A1 (ja) |
CZ (1) | CZ288503B6 (ja) |
DE (1) | DE69428665T2 (ja) |
DK (1) | DK0659413T3 (ja) |
ES (1) | ES2162845T3 (ja) |
HU (1) | HUT71329A (ja) |
IL (1) | IL112045A (ja) |
NO (1) | NO944929L (ja) |
NZ (1) | NZ270181A (ja) |
PH (1) | PH31328A (ja) |
PT (1) | PT659413E (ja) |
RU (1) | RU2138261C1 (ja) |
SI (1) | SI0659413T1 (ja) |
UA (1) | UA27004C2 (ja) |
ZA (1) | ZA9410082B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5492927A (en) * | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
US5512296A (en) * | 1994-08-22 | 1996-04-30 | Eli Lilly And Company | Methods for inhibiting neuronal damage |
EP0716854A3 (en) * | 1994-10-20 | 1996-08-28 | Lilly Co Eli | Compositions for inhibiting neuropeptide Y |
US6562862B1 (en) * | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
WO1998046588A2 (en) | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
US5990129A (en) * | 1997-09-23 | 1999-11-23 | Eli Lilly And Company | Methods for regulating trkA expression |
US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
ATE301129T1 (de) | 1999-05-04 | 2005-08-15 | Strakan Int Ltd | Androgen glykoside und die androgenische aktivität davon |
KR20030075998A (ko) * | 2002-03-22 | 2003-09-26 | 임은규 | 목욕용 생약제 조성물 |
US20060275806A1 (en) * | 2005-05-11 | 2006-12-07 | Schwartz David C | Whole genome methylation profiles via single molecule analysis |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE637389A (ja) * | 1962-09-13 | |||
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4380635A (en) | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4729999A (en) | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
TW383306B (en) | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
US5482949A (en) | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
US5445941A (en) | 1993-06-21 | 1995-08-29 | Eli Lilly And Company | Method for screening anti-osteoporosis agents |
DE4320896A1 (de) | 1993-06-24 | 1995-01-05 | Denecke Rainer Dr Med Vet | Präparat zur Therapie und Prophylaxe von Demenz-Erkrankungen |
CZ285522B6 (cs) | 1993-06-24 | 1999-08-11 | Eli Lilly And Company | Farmaceutický prostředek pro snížení koncentrace glukosy v krvi |
TW303299B (ja) | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
US5441947A (en) | 1993-08-25 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting vascular restenosis |
US5468773A (en) | 1993-08-25 | 1995-11-21 | Eli Lilly And Company | Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs |
US5391557A (en) * | 1993-10-15 | 1995-02-21 | Eli Lilly And Company | Methods for the treatment of peri-menopausal syndrome |
US5462950A (en) | 1993-12-21 | 1995-10-31 | Eli Lilly And Company | Methods of treating menstrual symptoms and compositions therefore |
US5578613A (en) | 1993-12-21 | 1996-11-26 | Eli Lilly And Company | Methods for inhibiting weight gain or inducing weight loss |
US5534526A (en) | 1993-12-21 | 1996-07-09 | Eli Lilly And Company | Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome |
US5389670A (en) | 1993-12-21 | 1995-02-14 | Eli Lilly Company | Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder |
US5552415A (en) | 1993-12-21 | 1996-09-03 | Eli Lilly And Company | Method of inhibiting Alzheimer's Disease |
US5492927A (en) * | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
US5439931A (en) | 1993-12-21 | 1995-08-08 | Eli Lilly And Company | Method for increasing libido in post-menopausal women |
US5512296A (en) | 1994-08-22 | 1996-04-30 | Eli Lilly And Company | Methods for inhibiting neuronal damage |
US5434166A (en) | 1994-08-22 | 1995-07-18 | Eli Lilly And Company | Methods of inhibiting demyelinating and desmyelinating diseases |
JP4111352B2 (ja) | 1996-05-21 | 2008-07-02 | 新日鐵住金ステンレス株式会社 | ステンレス鋼の高清浄化精錬法 |
-
1993
- 1993-12-21 US US08/171,388 patent/US6417198B1/en not_active Expired - Fee Related
-
1994
- 1994-12-19 RU RU94045277A patent/RU2138261C1/ru active
- 1994-12-19 EP EP94309470A patent/EP0659413B1/en not_active Expired - Lifetime
- 1994-12-19 NZ NZ270181A patent/NZ270181A/xx unknown
- 1994-12-19 HU HU9403679A patent/HUT71329A/hu unknown
- 1994-12-19 CN CN94119267A patent/CN1107332A/zh active Pending
- 1994-12-19 ES ES94309470T patent/ES2162845T3/es not_active Expired - Lifetime
- 1994-12-19 SI SI9430401T patent/SI0659413T1/xx unknown
- 1994-12-19 DE DE69428665T patent/DE69428665T2/de not_active Expired - Fee Related
- 1994-12-19 PH PH49591A patent/PH31328A/en unknown
- 1994-12-19 PT PT94309470T patent/PT659413E/pt unknown
- 1994-12-19 ZA ZA9410082A patent/ZA9410082B/xx unknown
- 1994-12-19 NO NO944929A patent/NO944929L/no not_active Application Discontinuation
- 1994-12-19 IL IL11204594A patent/IL112045A/en not_active IP Right Cessation
- 1994-12-19 AU AU81562/94A patent/AU692491B2/en not_active Ceased
- 1994-12-19 AT AT94309470T patent/ATE206920T1/de not_active IP Right Cessation
- 1994-12-19 KR KR1019940034933A patent/KR950016742A/ko not_active Application Discontinuation
- 1994-12-19 CA CA002138459A patent/CA2138459A1/en not_active Abandoned
- 1994-12-19 JP JP6314558A patent/JPH07196502A/ja active Pending
- 1994-12-19 DK DK94309470T patent/DK0659413T3/da active
- 1994-12-19 CZ CZ19943225A patent/CZ288503B6/cs not_active IP Right Cessation
- 1994-12-19 UA UA94129190A patent/UA27004C2/uk unknown
-
1995
- 1995-04-28 US US08/432,438 patent/US5663184A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
PT659413E (pt) | 2002-02-28 |
CN1107332A (zh) | 1995-08-30 |
CA2138459A1 (en) | 1995-06-22 |
RU2138261C1 (ru) | 1999-09-27 |
NO944929D0 (no) | 1994-12-19 |
JPH07196502A (ja) | 1995-08-01 |
IL112045A0 (en) | 1995-03-15 |
DE69428665D1 (de) | 2001-11-22 |
DE69428665T2 (de) | 2002-07-11 |
US6417198B1 (en) | 2002-07-09 |
HUT71329A (en) | 1995-11-28 |
IL112045A (en) | 1999-03-12 |
CZ322594A3 (en) | 1995-08-16 |
ATE206920T1 (de) | 2001-11-15 |
AU692491B2 (en) | 1998-06-11 |
CZ288503B6 (cs) | 2001-07-11 |
KR950016742A (ko) | 1995-07-20 |
RU94045277A (ru) | 1996-11-10 |
PH31328A (en) | 1998-07-06 |
ZA9410082B (en) | 1996-06-19 |
NZ270181A (en) | 1997-08-22 |
HU9403679D0 (en) | 1995-02-28 |
AU8156294A (en) | 1995-06-29 |
US5663184A (en) | 1997-09-02 |
ES2162845T3 (es) | 2002-01-16 |
EP0659413A2 (en) | 1995-06-28 |
DK0659413T3 (da) | 2001-12-03 |
EP0659413A3 (en) | 1995-10-11 |
EP0659413B1 (en) | 2001-10-17 |
SI0659413T1 (en) | 2002-04-30 |
UA27004C2 (uk) | 2000-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO943878L (no) | Hemming av uterinfibrose | |
NO944929D0 (no) | Fremgangsmåte for å inhibere CNS-problemer i post-menopausale kvinner | |
NO944925L (no) | Fremgangsmåte for å öke libido i post-menopausale kvinner | |
GR3027706T3 (en) | Inhibition of dysfunctional uterine bleeding. | |
ZA948027B (en) | Methods for inhibiting angiogenesis and angiogenic diseases | |
NO944920L (no) | Fremgangsmåte for å inhibere hirsutisme og alopecia hos kvinner |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |